Read by QxMD icon Read

infusion chemotherapy

Boaz Nachmias, Adir Shaulov, Moshe E Gatt, Michael Shapira, Alexander Gural
The treatment of relapsed/refractory acute lymphoblastic leukemia (RR-ALL) presents a true clinical challenge. In 2012, a protocol combining bortezomib, dexamethasone, asparaginase, doxorubicin, and vincristine administered to children with RR-ALL was published with encouraging results. Over the past 5 years, we have implemented this protocol in the adult RR-ALL population (> 18 years) and addressed its feasibility in terms of remission rate and toxicity. Here, we present the results of our experience in 9 patients, all of whom received multiple previous chemotherapy protocols, two of them relapsing after an allogeneic bone marrow transplantation...
October 19, 2018: Acta Haematologica
Kuixing Zhang, Daniel Farrell, Deepa Jeyakumar, Susan O'Brien, Xiaohui Zhao, Sherif A Rezk
Although rare cases of prolymphocytic transformation from splenic B-cell lymphomas and follicular lymphoma have been reported, prolymphocytic transformation from lymphoplasmacytic lymphoma has not been previously reported. We report a case of 76-year old male patient with a history of Waldenström's Macroglobulinemia diagnosed in 2010 and treated with infusion chemotherapy. He was in clinical remission for 5years. In 2016, he presented with diffuse lymphadenopathy and a head and neck lymph node biopsy showed lymphoplasmacytic lymphoma...
October 17, 2018: Human Pathology
Joseph M Brandwein, Jack T Seki, Eshetu G Atenafu, Amr Rostom, Andrzej Lutynski, Anna Rydlewski, Aaron D Schimmer, Andre C Schuh, Vikas Gupta, Karen W L Yee
Despite the widespread use of 5-HT3 antagonists as anti-emetic prophylaxis in patients with acute myeloid leukemia (AML) receiving induction chemotherapy, nausea and vomiting persist in many cases. We performed a Phase II single-arm study evaluating the use of aprepitant on days 1-5, in combination with a 5-HT antagonist on days 1-3, in AML patients undergoing induction chemotherapy with daunorubicin on days 1-3 plus cytarabine, given as a continuous infusion, on days 1-7. This was compared to a retrospective cohort of AML patients that received the same chemotherapy regimen with a 5-HT antagonist but without aprepitant...
October 19, 2018: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
Ryan D Nipp, Margaret Ruddy, Charn-Xin Fuh, Mark L Zangardi, Christine Chio, E Bridget Kim, Barbara Kong Mui Li, Ying Long, Gayle C Blouin, Daniel Lage, David P Ryan, Joseph A Greer, Areej El-Jawahri, Jennifer S Temel
BACKGROUND: Oncology clinicians often struggle with managing medications and vaccinations in older adults with cancer. We sought to demonstrate the feasibility and preliminary efficacy of integrating pharmacists into the care of older adults with cancer to enhance medication management and vaccination administration. METHODS: We randomly assigned patients aged ≥65 years with breast, gastrointestinal, or lung cancer receiving first-line chemotherapy to the pharmacy intervention or usual care...
October 19, 2018: Oncologist
Brian H Kushner, Irene Y Cheung, Shakeel Modak, Ellen M Basu, Stephen S Roberts, Nai-Kong Cheung
Importance: Chimeric and murine anti-GD2 antibodies are active against neuroblastoma, but the development of neutralizing antibodies can compromise efficacy. To decrease immunogenicity, hu3F8, a humanized anti-GD2 antibody, was constructed. Objective: To find the maximum-tolerated dose of hu3F8 with granulocyte-macrophage colony-stimulating factor. Design, Setting, and Participants: This phase 1 clinical trial used a 3 + 3 dose-escalation design in a single referral center (Memorial Sloan Kettering Cancer Center, New York, New York)...
September 20, 2018: JAMA Oncology
Rudolph M Navari, Lee S Schwartzberg
To examine pharmacologic and clinical characteristics of neurokinin 1 (NK1 )-receptor antagonists (RAs) for preventing chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy, a literature search was performed for clinical studies in patients at risk of CINV with any approved NK1 RAs in the title or abstract: aprepitant (capsules or oral suspension), HTX019 (intravenous [IV] aprepitant), fosaprepitant (IV aprepitant prodrug), rolapitant (tablets or IV), and fixed-dose tablets combining netupitant or fosnetupi-tant (IV netupitant prodrug) with the 5-hydroxytryptamine type 3 (5HT3 ) RA palonosetron (oral or IV)...
2018: OncoTargets and Therapy
Kathelijne Cjm Kraal, Ilse Timmerman, Hannah M Kansen, Cor van den Bos, Jozsef Zsiros, Henk van den Berg, Sebastiaan F Somers, Eric Braakman, Annemarie M L Peek, Max van Noesel, C Ellen van der Schoot, Marta Fiocco, Huib N Caron, Carlijn Voermans, Godelieve A M Tytgat
PURPOSE: Targeted radiotherapy with 131 Iodine-meta-iodobenzylguanidine (131 I-MIBG) is effective for neuroblastoma (NBL), although optimal scheduling during high-risk (HR) treatment is being investigated. We aimed to evaluate the feasibility of stem cell apheresis and study hematological reconstitution after autologous stem cell transplantation (ASCT) in HR-NBL patients treated with upfront 131 I-MIBG-therapy. EXPERIMENTAL DESIGN: In two prospective multi-center cohort studies, newly diagnosed HR-NBL patients were treated with two courses of 131 I-MIBG-therapy, followed by a HR-induction protocol...
October 12, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Chun-Shuang Guan, Xue-Mei Wang, Zhi-Bin Lv, Shuo Yan, Lei Sun, Ru-Ming Xie
RATIONALE: Kaposi's sarcoma (KS) is the most common malignant tumor in HIV-infected people and occurs mainly in the skin, mucous membranes, and lymph nodes. Approximately 33% of the initial skin manifestations of AIDS and approximately 35% to 79% of KS occur during disease progression. Otherwise, AIDS-related facial KS that was simultaneously examined by magnetic resonance imaging (MRI) is rare. PATIENT CONCERNS: This case was a 30-year-old male homosexual, with left facial nodule for 14 months, and HIV infection was diagnosed 1 month previously...
October 2018: Medicine (Baltimore)
Mengying Hong, Kejun Tang, Jing Qian, Hongyu Deng, Musheng Zeng, Shu Zheng, Kefeng Ding, Yushen Du, Ren Sun
Epstein-Barr virus (EBV)-associated nasopharyngeal carcinoma (NPC) is one of the most common head and neck malignancies in southern China and Southeast Asia. Unfortunately, 70% of NPC patients have locally advanced disease at the first diagnosis. Radiotherapy alone and concurrent chemoradiotherapy are important treatment approaches for NPC, but they have a limited effect on patients with locally advanced or distantly metastatic disease. 1-5 Nevertheless, the unique immune environment of the EBV-associated NPC provides rational targets for immunotherapy...
2018: Critical Reviews in Oncogenesis
Issei Saeki, Takahiro Yamasaki, Masaki Maeda, Takuro Hisanaga, Takuya Iwamoto, Koichi Fujisawa, Toshihiko Matsumoto, Isao Hidaka, Yoshio Marumoto, Tsuyoshi Ishikawa, Naoki Yamamoto, Yutaka Suehiro, Taro Takami, Isao Sakaida
Sorafenib is used worldwide as a first-line standard systemic agent for advanced hepatocellular carcinoma (HCC) on the basis of the results of two large-scale Phase III trials. Conversely, hepatic arterial infusion chemotherapy (HAIC) is one of the most recommended treatments in Japan. Although there have been no randomized controlled trials comparing sorafenib with HAIC, several retrospective analyses have shown no significant differences in survival between the two therapies. Outcomes are favorable for HCC patients exhibiting macroscopic vascular invasion when treated with HAIC rather than sorafenib, whereas in HCC patients exhibiting extrahepatic spread or resistance to transcatheter arterial chemoembolization, good outcomes are achieved by treatment with sorafenib rather than HAIC...
September 27, 2018: World Journal of Hepatology
Naoya Hashimoto, Seiichiro Mitani, Hiroya Taniguchi, Yukiya Narita, Kyoko Kato, Toshiki Masuishi, Shigenori Kadowaki, Sachiyo Onishi, Masahiro Tajika, Shinji Takahashi, Kazuhiro Shimomura, Chihoko Takahata, Eri Hotta, Makiko Kobara, Kei Muro
LESSONS LEARNED: A shortened infusion of ramucirumab (from 60 to 20 minutes) was safe and feasible without infusion-related reactions.Twenty-minute infusions of ramucirumab can be an option for patients with no infusion-related reactions during the first 60-minute treatment. BACKGROUND: Ramucirumab is usually administered over 60 minutes, during which it is unlikely to cause infusion-related reactions (IRRs). This prospective study evaluated the safety of a shortened infusion of ramucirumab...
October 10, 2018: Oncologist
Hiroyuki Amagai, Kentaro Murakami, Haruhito Sakata, Masaya Uesato, Koichi Hayano, Masayuki Kano, Takeshi Fujishiro, Takeshi Toyozumi, Senba Yoshihide, Kohei Yamamoto, Hideki Hayashi, Hisahiro Matsubara
Introduction Cancer patients undergoing hemodialysis might be under-treated because the pharmacokinetics of anti-cancer drugs in such patients remain unknown and out of concern related to the potential development of severe adverse effects. However, patients with chemosensitive cancer, such as esophageal cancer, should receive chemotherapy at a dose that is sufficient to attain a favorable therapeutic effect. We herein present an interesting case involving an esophageal cancer patient who was successfully treated with subtotal thoracic esophagectomy, and adjuvant full-dose chemotherapy with cisplatin and 5-fluorouracil while concomitantly undergoing hemodialysis...
October 10, 2018: Journal of Oncology Pharmacy Practice
Ralph Boccia, Robert B Geller, Neil Clendeninn, Thomas Ottoboni
AIM: Fosaprepitant, an intravenous neurokinin-1 receptor antagonist for chemotherapy-induced nausea and vomiting, contains polysorbate 80, which is associated with infusion-site adverse events (ISAEs) and hypersensitivity systemic reactions (HSRs). This study investigated ISAEs/HSRs following fosaprepitant with anthracycline-containing chemotherapy. PATIENTS & METHODS: This retrospective chart review noted ISAEs/HSRs following the anthracycline doxorubicin+cyclophosphamide and a three-drug fosaprepitant regimen, via peripheral line...
October 10, 2018: Future Oncology
José Alfonso Alvarez-Rodríguez, Mario García-Suárez, Daniel Fernández-García, Carlos Méndez-Martínez, Juan Gómez-Salgado
The aim of this study was to analyse the characteristics of central venous catheters with brachial-implanted reservoirs and the complications associated with their use over a 4-years period. This observational study was carried out in an onco-haematological day hospital in Spain. Information was collected about 125 catheters inserted in patients requiring intravenous chemotherapy. There were more catheters implanted in women than men and the mean age was 58.6 years. Seventy of the implanted catheters were made of polyurethane and 55 of silicone...
October 9, 2018: European Journal of Cancer Care
Su Ho Kim, Jung Suk Oh, Ho Jong Chun, Byung Gil Choi, Hae Giu Lee
PURPOSE: To compare the feasibility and safety of mono-port catheter system and dual-port catheter system for advanced hepatocellular carcinoma (HCC) in patients with anatomic hepatic artery variation and portal vein tumor thrombosis. MATERIALS AND METHODS: This retrospective study consisted of 22 patients with infiltrative or multiple HCC with unilateral or bilateral portal vein thrombosis who had hepatic artery variation. A mono-port or dual-port catheter system was determined according to the degree of blood supply to the entire tumor through the common hepatic and variant hepatic arteries...
October 5, 2018: Journal of Vascular and Interventional Radiology: JVIR
Huifang Lu, Anna S Lok, Carla L Warneke, Sairah Ahmed, Harrys A Torres, Fernando Martinez, Maria E Suarez-Almazor, Jessica T Foreman, Alessandra Ferrajoli, Jessica P Hwang
BACKGROUND: Patients previously infected with hepatitis B virus (HBV; indicated by positivity for anti-HBc) can experience HBV reactivation during cancer chemotherapy. Intravenous immunoglobulin infusion, which is frequently used in supportive care, might facilitate passive transfer of anti-HBc. We aimed to estimate the probability of passive transfer of anti-HBc after intravenous immunoglobulin infusion in patients with cancer. METHODS: We reviewed institutional databases to identify adult patients who received outpatient chemotherapy between Jan 1, 2004, and Dec 31, 2011, at the University of Texas MD Anderson Cancer Center, Houston, TX, USA...
October 2018: Lancet Haematology
Peter B Soeters, Robert R Wolfe, Alan Shenkin
Hypoalbuminemia is associated with inflammation. Despite being addressed repeatedly in the literature, there is still confusion regarding its pathogenesis and clinical significance. Inflammation increases capillary permeability and escape of serum albumin, leading to expansion of interstitial space and increasing the distribution volume of albumin. The half-life of albumin has been shown to shorten, decreasing total albumin mass. These 2 factors lead to hypoalbuminemia despite increased fractional synthesis rates in plasma...
October 4, 2018: JPEN. Journal of Parenteral and Enteral Nutrition
Sandra Lockmer, Bjørn Østenstad, Hans Hagberg, Harald Holte, Ann-Sofie Johansson, Björn Engelbrekt Wahlin, Karin Fahl Wader, Chloé Beate Steen, Peter Meyer, Martin Maisenhølder, Karin Ekström Smedby, Peter Brown, Eva Kimby
PURPOSE: For indolent lymphoma, the optimal timing, sequence, and choice of therapeutic regimens remain a matter of debate. In two Nordic Lymphoma Group randomized trials, symptomatic or clearly progressing patients were treated first line with a rituximab-containing regimen without chemotherapy. The purpose of this study was to assess long-term survival, risk of transformation, and need of new therapies. METHODS: Data were collected at cross-sectional follow-up for 321 patients with indolent lymphoma (84% with follicular lymphomas [FL]) included in one of two Nordic Lymphoma Group trials (accrual 1998 to 1999 and 2002 to 2008)...
October 4, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Tariq Almerey, Emmanuel M Gabriel, Klaus D Torp, Sanjay P Bagaria
BACKGROUND: Multiple studies highlight the importance of liberal fluid administration in cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). Over-resuscitation can delay recovery and wound healing. We report an intraoperative protocol that restricts fluid administration and minimizes morbidity. MATERIALS AND METHODS: Retrospective analysis of 35 patients that underwent CRS-HIPEC for curative intent under fluid restriction protocol from June 2015 to July 2017 was performed...
November 2018: Journal of Surgical Research
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"